NCT02960035View on ClinicalTrials.gov

A Study of the MASEI in the Treatment of Anti-TNF Blocker to Peripheral Tendonitis in Patients With Spondyloarthritis

PHASE4CompletedINTERVENTIONAL
Enrollment

96

Participants

Timeline

Start Date

April 30, 2014

Primary Completion Date

September 30, 2016

Study Completion Date

October 31, 2018

Conditions
Spondyloarthropathy
Interventions
DRUG

50mg etanercept

Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ IgG Fc Fusion Protein Injection, 50mg per week

DRUG

25mg etanercept

Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ IgG Fc Fusion Protein Injection, 25mg per week

DRUG

placebo

Trial Locations (1)

Unknown

Department of Rheumatology, the Third Affiliated Hospital of Sun Yat-sen University, Guangzhou

All Listed Sponsors
lead

Sun Yat-sen University

OTHER

NCT02960035 - A Study of the MASEI in the Treatment of Anti-TNF Blocker to Peripheral Tendonitis in Patients With Spondyloarthritis | Biotech Hunter | Biotech Hunter